Mind Medicine Australia, a partner with Optimi since
"Australian psychiatrists can now prescribe Optimi’s MDMA and psilocybin capsules for therapeutic use in patients, which is a very humbling achievement," remarked JJ Wilson, Co-Founder and Chair of
To further support this initiative, Optimi has developed a secure Prescriber Portal set to launch in
"We are thrilled to reach this pivotal moment, made possible by the tremendous hard work and dedication from both our team and our partners at
A
Mind Medicine Australia is dedicated to ensuring that psychedelic-assisted therapies are available to psychiatrists and patients at the most cost-effective rates. Optimi CEO
Mind Medicine Australia’s highly regarded certificate in psychedelic-assisted therapies has now graduated over 350 professionals, many of whom describe it as the best professional development program they have ever participated in. The course equips qualified clinicians with the necessary skills and awareness to safely and effectively facilitate psychedelic-assisted therapies, alongside guidance on a range of other critical therapeutic skills.
Currently, there are 10 Authorised Prescribers in
Ensuring Timely
This inaugural delivery of GMP MDMA and psilocybin ensures that authorised psychiatrists and their patients across
Optimi is proud to be at the forefront of this historic development in psychedelic therapy and looks forward to continuing its work with MMA to bring these innovative treatments to those in need.
For media inquiries, please contact
michaelk@optimihealth.ca
902.880.6121
For investor inquiries, please contact:
investors@optimihealth.ca
www.optimihealth.ca
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)
FORWARD‐LOOKING STATEMENTS
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. forward-looking statements made in this news release include the proposed use of the proceeds of the Offering. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the
![](https://ml.globenewswire.com/media/NzZiYjU0NWEtOGJhMS00YTA0LTk3MWEtNDVjZmIyMzhkOWJjLTEyMTQ5MzY=/tiny/Optimi-Health-Corp-.png)
2024 GlobeNewswire, Inc., source